DE69612962D1 - Epoxysuccinamid-derivate oder deren salze und medikamente die diese enthalten - Google Patents

Epoxysuccinamid-derivate oder deren salze und medikamente die diese enthalten

Info

Publication number
DE69612962D1
DE69612962D1 DE69612962T DE69612962T DE69612962D1 DE 69612962 D1 DE69612962 D1 DE 69612962D1 DE 69612962 T DE69612962 T DE 69612962T DE 69612962 T DE69612962 T DE 69612962T DE 69612962 D1 DE69612962 D1 DE 69612962D1
Authority
DE
Germany
Prior art keywords
aralkyl group
group
substituted
aromatic hydrocarbon
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69612962T
Other languages
English (en)
Other versions
DE69612962T2 (de
Inventor
Tomohiro Yamashita
Yoshimitsu Suda
Yukio Tada
Nobuhiko Katsunuma
Tetsuji Asao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE69612962D1 publication Critical patent/DE69612962D1/de
Publication of DE69612962T2 publication Critical patent/DE69612962T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/48—Compounds containing oxirane rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69612962T 1995-12-12 1996-12-10 Epoxysuccinamid-derivate oder deren salze und medikamente die diese enthalten Expired - Fee Related DE69612962T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP32297195 1995-12-12
PCT/JP1996/003603 WO1997021694A1 (fr) 1995-12-12 1996-12-10 Derives d'epoxysuccinamides ou sels de ces derives, et medicaments les contenant

Publications (2)

Publication Number Publication Date
DE69612962D1 true DE69612962D1 (de) 2001-06-28
DE69612962T2 DE69612962T2 (de) 2001-11-15

Family

ID=18149701

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69612962T Expired - Fee Related DE69612962T2 (de) 1995-12-12 1996-12-10 Epoxysuccinamid-derivate oder deren salze und medikamente die diese enthalten

Country Status (9)

Country Link
US (1) US5883121A (de)
EP (1) EP0808839B1 (de)
JP (1) JP3338452B2 (de)
KR (1) KR100226461B1 (de)
AT (1) ATE201404T1 (de)
AU (1) AU697565B2 (de)
CA (1) CA2211128C (de)
DE (1) DE69612962T2 (de)
WO (1) WO1997021694A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0921122B1 (de) * 1997-04-18 2003-05-21 Taiho Pharmaceutical Company, Limited Epoxysuccinamid-derivate oder ihre salze
NZ511710A (en) * 1998-12-23 2003-12-19 Smithkline Beecham Corp 4-Amino-azepan-3-one derivatives useful as protease inhibitors
EP1384713B1 (de) * 1998-12-23 2008-10-15 SmithKline Beecham Corporation 4-Amino-azepan-3-on-Derivate als Protease-Inhibitors
US6605589B1 (en) 2000-03-31 2003-08-12 Parker Hughes Institute Cathepsin inhibitors in cancer treatment
US6620844B2 (en) * 2001-02-14 2003-09-16 Newmillennium Pharmaceutical, Inc. Method for reducing blood insulin levels by reducing in vivo cathepsin L activity
US20040009891A1 (en) * 2001-02-14 2004-01-15 Newmillennium Pharmaceutical, Inc. Method and composition for treating obesity by targeting cathepsin
WO2004084830A2 (en) * 2003-03-21 2004-10-07 Buck Institute Method for treating alzheimer’s dementia
US9144594B2 (en) * 2005-11-08 2015-09-29 University Of Miami Cathepsin L mediated diseases and associated methods and products
US7670817B2 (en) * 2005-11-08 2010-03-02 The General Hospital Corporation Dynamin mediated diseases and associated methods and products
EP2029135A4 (de) * 2006-06-13 2011-08-17 Univ Leland Stanford Junior Epoxidhemmer von zysteinproteasen
CN101970007A (zh) 2007-06-08 2011-02-09 日本化学医药株式会社 脑动脉瘤的治疗或预防药
JPWO2009054454A1 (ja) 2007-10-24 2011-03-03 国立大学法人 東京医科歯科大学 カテプシン阻害剤を有効成分として含有するＴｏｌｌ様受容体のシグナル伝達の調整剤
AU2013365769B2 (en) * 2012-12-18 2018-03-15 Jawaharlal Nehru Centre For Advanced Scientific Research Antimicrobial compounds, their synthesis and applications thereof
CN107151236B (zh) 2016-03-03 2021-04-30 中国人民解放军军事医学科学院毒物药物研究所 一种2,3-环氧丁二酰衍生物及其制备方法和用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5556853A (en) * 1993-10-29 1996-09-17 Takeda Chemical Industries, Ltd. Epoxysuccinic acid derivatives
US5438267A (en) * 1994-01-26 1995-08-01 Baker Hughes Incorporated Single-switching method of eliminating the effect of electromagnetic coupling between a pair of receivers

Also Published As

Publication number Publication date
AU697565B2 (en) 1998-10-08
JP3338452B2 (ja) 2002-10-28
US5883121A (en) 1999-03-16
DE69612962T2 (de) 2001-11-15
AU1041497A (en) 1997-07-03
KR19980701741A (ko) 1998-06-25
CA2211128A1 (en) 1997-06-19
EP0808839A1 (de) 1997-11-26
EP0808839A4 (de) 1998-12-02
CA2211128C (en) 2001-02-06
ATE201404T1 (de) 2001-06-15
WO1997021694A1 (fr) 1997-06-19
EP0808839B1 (de) 2001-05-23
KR100226461B1 (ko) 1999-10-15

Similar Documents

Publication Publication Date Title
DE69612962D1 (de) Epoxysuccinamid-derivate oder deren salze und medikamente die diese enthalten
BR9810137A (pt) Composto, composição farmacêutica e método de tratamento ou prevenção de uma desordem tromoboembólica
TW218018B (de)
ES2150489T3 (es) 1-amidinofenil-pirrolidonas, -piperidinonas, -azetinonas como inhibidores de la agregacion de plaquetas.
DK0627406T3 (da) 2-Amino-1,3-propandiolforbindelser og immunundertrykkende midler
ES2197160T3 (es) Antagonistas fibronogeno bicicliclos.
TW430660B (en) Novel benzindole derivatives for neuron cell protection, processes for production, and the pharmaceutical compounds containing them
DE69820248D1 (de) Pyrrolidin-derivate die eine phospholipase-a2-hemmende wirkung haben
DE69727915D1 (de) Substituierte vinylpyridinderivate und arzneimittel, die diese enthalten
HUT70194A (en) Quinoline- or quinazoline derivatives, process for producing them and pharmaceutical compositions containing them
ATE247089T1 (de) Pyridoncarbonsäurederivate oder ihre salze und diese als aktive bestandteile enthaltende medikamente
EP0607864A3 (de) Tricyclische kondensierte heterocyclische Verbindungen zur Behandlung von seniler Demenz.
DE69814800D1 (de) Epoxysuccinamid-derivate oder ihre salze
DE69332366T2 (de) Arylsubstituierte heterocyclische Verbindungen
DE69329184T2 (de) Alkylsubstituierte heterocyclische Verbindungen
ATE273974T1 (de) Benzoxazolderivate und medikamente die diese als aktiven wirkstoff enthalten
ATE88634T1 (de) Arzneimittel zur behandlung von herzinsuffizienz.
TH18027A (th) อนุพันธ์ของอีพอกซิซัคฟินิคแอซิด
TH53245A3 (th) อนุพันธ์เบนซอกซาโซลและยาที่ประกอบรวมด้วยอนุพันธ์ดังกล่าวในฐานะสารออกฤทธิ์
PL342826A1 (en) Derivatives of cycloalkenes, their production and application
TH18027EX (th) อนุพันธ์ของอีพอกซิซัคฟินิคแอซิด

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee